Identification of PI3K/AKT pathway related gene mutations in triple-negative breast cancer and their association with response to PI3K inhibitors
Year: 2026
Type: dissertation
Abstract: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, characterised by high recurrence rates, poor prognosis, and limited targeted therapies due to absence of hormone receptors and HER2 expression. Although TNBC frequently harbours TP53 and PI3K pathway alterations, their combined functional impact as an integrated molecular phenotype remains underexplored. This thesis defines a TP53-PI3K pathway-activated (TP53-PI3Kact) subgroup characterised by co-occurring TP53 mutation and PI3K pathway activation (PIK3CA mutation, AKT1 mutation, or PTEN loss). Using METABRIC and TCGA TNBC cohorts, integrated genomic and transcriptomic analyses assessed prevalence, survival, and molecular features. Proteomic analyses were also incorporated to refine pathway activity signatures and improve subgroup stratification across cohorts. TP53-PI3Kact tumours showed significantly poorer survival independent of clinical covariates and TNBC subtype, with enrichment of PI3K/AKT signalling, metabolic reprogramming, inflammatory signalling, and BL2/LAR transcriptional programmes. Functional studies in TNBC cell lines demonstrated resistance to PI3K inhibitor alpelisib in TP53/PIK3CA co-mutant cells, which was overcome by dual PI3K and RTK inhibition, leading to synergistic anti-proliferative and pro-apoptotic effects. This combination more effectively suppressed PI3K/AKT signalling and downstream effectors, including 4E-BP1. In isogenic MCF10A models, TP53 missense variants showed allele-specific effects on alpelisib response, with DNA-contact mutants more sensitive than structural mutants. Introduction of PIK3CAH1047R reduced alpelisib sensitivity across TP53 backgrounds, while combination therapy enhanced efficacy with context-dependent synergy. Overall, TP53-PI3Kact defines a convergent oncogenic state characterised by signalling and metabolic reprogramming and poor outcomes, representing a distinct and targetable TNBC subset. In this context, dual PI3K and RTK inhibition may overcome adaptive resistance, although therapeutic response is strongly influenced by TP53 variant class and PI3K pathway genotype. These findings support integration of TP53 and PI3K pathway status into future clinical stratification and trial design, and highlight the need for genotype-informed combination strategies to overcome heterogeneous therapeutic resistance in TNBC.
Author: Colley, Grace
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7225841523
